CSIMarket
 


Atara Biotherapeutics, Inc.  (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Capital Expenditures Growth by Quarter and Year

Atara Biotherapeutics,'s Capital Expenditures results by quarter and year




ATRA Capital Expenditures (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - 4.17 9.70 1.38
III Quarter September - 4.50 6.19 0.75
II Quarter June 0.74 7.45 3.14 0.89
I Quarter March 0.80 19.81 1.21 0.27
FY   1.54 35.93 20.24 3.29



ATRA Capital Expenditures second quarter 2019 Y/Y Growth Comment
Atara Biotherapeutics, Inc. reported drop in Capital Expenditures in the second quarter by -90.09% to $ 0.74 millions, from the same quarter in 2018.
The fall in the second quarter Atara Biotherapeutics, Inc.'s Capital Expenditures compares unfavorably to the Company's average Capital Expenditures decline of -39.68%.

Looking into second quarter results within Biotechnology & Drugs industry 68 other companies have achieved higher Capital Expenditures growth. While Atara Biotherapeutics, Inc.' s Capital Expenditures meltdown of -90.09% ranks overall at the positon no. 2247 in the second quarter.




ATRA Capital Expenditures ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - -57.01 % 602.9 % 13700 %
III Quarter September - -27.3 % 725.33 % -
II Quarter June -90.09 % 137.26 % 252.81 % 8800 %
I Quarter March -95.96 % 1537.19 % 348.15 % -
FY   - 77.52 % 515.2 % -

Financial Statements
Atara Biotherapeutics,'s second quarter 2019 Capital Expenditures $ 0.74 millions ATRA's Income Statement
Atara Biotherapeutics,'s second quarter 2018 Capital Expenditures $ 7.45 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Capital Expenditures Growth >>


ATRA Capital Expenditures (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - -7.33 % 56.7 % 84 %
III Quarter September - -39.6 % 97.13 % -15.73 %
II Quarter June -7.75 % -62.39 % 159.5 % 229.63 %
I Quarter March -80.82 % 104.23 % -12.32 % 2600 %
FY (Year on Year)   - 77.52 % 515.2 % -




Capital Expenditures second quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #69
Healthcare Sector #323
Overall #2247

Capital Expenditures Y/Y Growth Statistics
High Average Low
-39.68 % -39.68 % -39.68 %
(Jun 30 2019)  
Capital Expenditures second quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #69
Healthcare Sector #323
Overall #2247
Capital Expenditures Y/Y Growth Statistics
High Average Low
-39.68 % -39.68 % -39.68 %
(Jun 30 2019)  

Capital Expenditures by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Atara Biotherapeutics,'s Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 137.11 % -100 %
(Dec 31 2015)  


ATRA's II. Quarter Q/Q Capital Expenditures Comment
In the II. Quarter 2019 Atara Biotherapeutics, Inc. reported drop in Capital Expenditures from the previous quarter by -7.75% to $ 0.74 millions, from $ 0.80 millions released in the previous reporting period.

As we look into recent slump in the quarter, we suppose to take into consideration, that frequently II. Quarter 2019 results emerge softer in contrast to the first quarter, Adriana Nunes, Biotechnology & Drugs industry veteran situated in Porto added.

Within Biotechnology & Drugs industry 55 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics,'s Capital Expenditures growth quarter on quarter, overall rank is 1514.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #56
Healthcare Sector #243
Overall #1514
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #56
Healthcare Sector #243
Overall #1514
Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 137.11 % -100 %
(Dec 31 2015)  


ATRA's II. Quarter Q/Q Capital Expenditures Comment
In the II. Quarter 2019 Atara Biotherapeutics, Inc. realized drop in Capital Expenditures from the first quarter by -7.75% to $ 0.74 millions, from $ 0.80 millions achived a quarter before.

If you analyse current shortcoming in the II. Quarter 2019, you should assume, that usually II. Quarter Capital Expenditures occur weaker in contrast to the preciding period

Within Biotechnology & Drugs industry 55 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics,'s Capital Expenditures growth quarter on quarter, overall rank is 1514.


Atara Biotherapeutics,'s 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Jun 30 2019)
12 Months Ending
12 Months Ending
12 Months Ending
12 Months Ending
Cumulative Capital Expenditures 12 Months Ending $ 10.20 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) -76.36 % - - - -
Year on Year Capital Expenditures Growth Overall Ranking # 2253 # 0 # 334 # 138 # 16
Seqeuential Capital Expenditures Change (TTM) -39.68 % - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2247 # 0 # 1735 # 1704 # 761




Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics, showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in . If the fiscal year would end in Jun 30 2019, Atara Biotherapeutics,'s annual Capital Expenditures drop would be -76.36% year on year to $10 millions.

In the Healthcare sector 302 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 2253.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
-39.68 %
-39.68 %
-39.68 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 69
Healthcare Sector # 303
Overall # 2253

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-76.36 %
-76.36 %
-76.36 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 323
S&P 500 # 2247
Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics, showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in . If the fiscal year would end in Jun 30 2019, Atara Biotherapeutics,'s annual Capital Expenditures drop would be -76.36% year on year to $10 millions.

In the Healthcare sector 302 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 2253.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
-39.68 %
-39.68 %
-39.68 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 69
Healthcare Sector # 303
Overall # 2253

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-76.36 %
-76.36 %
-76.36 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 323
S&P 500 # 2247




Other Capital Expenditures Growth
Biotechnology & Drugs Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ATRA's Capital Expenditures Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ATRA's Competitors
Capital Expenditures Growth for Atara Biotherapeutics,'s Suppliers
Capital Expenditures Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Jun 30 2019 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Jun 30 2019
Rockwell Medical, Inc. -1.02 %$ -1.018 millions
Baxter International Inc -1.28 %$ -1.282 millions
Vbi Vaccines Inc -1.66 %$ -1.663 millions
Audentes Therapeutics, Inc. -2.16 %$ -2.158 millions
Laboratory Corp Of America Holdings -2.29 %$ -2.294 millions
Assembly Biosciences, Inc. -2.41 %$ -2.405 millions
Mylan N.v. -2.43 %$ -2.434 millions
National Healthcare Corp -2.88 %$ -2.884 millions
Icu Medical Inc -3.37 %$ -3.374 millions
Bristol Myers Squibb Co -3.54 %$ -3.535 millions
Neurocrine Biosciences Inc -4.09 %$ -4.092 millions
Cumberland Pharmaceuticals Inc. -4.21 %$ -4.207 millions
Sorrento Therapeutics, Inc. -4.40 %$ -4.399 millions
Hill-rom Holdings, Inc. -4.88 %$ -4.878 millions
Insulet Corporation -5.32 %$ -5.322 millions
Avrobio, Inc. -5.42 %$ -5.425 millions
Alkermes Plc. -6.09 %$ -6.094 millions
Healthcare Services Group Inc -6.22 %$ -6.225 millions
Alnylam Pharmaceuticals, Inc. -6.45 %$ -6.447 millions
Restorbio, Inc. -7.69 %$ -7.692 millions
Fibrogen Inc -7.76 %$ -7.762 millions
United Cannabis Corp -7.80 %$ -7.799 millions
Retrophin, Inc. -9.27 %$ -9.266 millions
Aimmune Therapeutics, Inc. -9.64 %$ -9.637 millions
Repro Med Systems Inc -9.66 %$ -9.662 millions
Coherent, Inc. -9.76 %$ -9.758 millions
Celldex Therapeutics, Inc. -10.24 %$ -10.241 millions
Ocular Therapeutix, Inc -11.33 %$ -11.331 millions
Integra Lifesciences Holdings Corp -11.68 %$ -11.680 millions
Durect Corp -11.76 %$ -11.765 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PFHS's Profile

Stock Price

PFHS's Financials

Business Description

Fundamentals

Charts & Quotes

PFHS's News

Suppliers

PFHS's Competitors

Customers & Markets

Economic Indicators

PFHS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071